A Phase I/II Trial of Fixed Doses of Daily Gefitinib With Escalating Doses of Daily RAD001 in Advanced Non-Small Cell Lung Cancer
Phase of Trial: Phase I/II
Latest Information Update: 25 Jan 2016
At a glance
- Drugs Everolimus (Primary) ; Gefitinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 08 Nov 2010 Actual end date (Jul 2010) added as reported by ClinicalTrials.gov.
- 08 Nov 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 26 Oct 2008 Planned end date changed from 1 May 2009 to 1 May 2010 as reported by ClinicalTrials.gov.